Rob McDonald

Rob McDonald has extensive work experience in the pharmaceutical industry, with their most recent role being Executive Director of Platform Biology at Kymera Therapeutics since July 2022. Prior to that, they served as Senior Director of Platform Biology at the same company from October 2021 to July 2022. Before joining Kymera Therapeutics, Rob worked at Novartis Institutes for BioMedical Research (NIBR) for a significant portion of their career. Rob held various roles at NIBR, including Associate Director from April 2020 to October 2021, Senior Investigator II from October 2019 to March 2020, Senior Investigator I from October 2014 to April 2019, Investigator III from April 2011 to October 2014, and Investigator II from November 2009 to April 2011. Prior to their time at NIBR, Rob worked as a Postdoctoral Researcher at Harvard Medical School from 2003 to 2009, conducting research on the cellular response to DNA damage.

Rob McDonald earned a Bachelor of Science (BS) degree in Biology, General from Syracuse University in 1995. Rob later obtained a PhD in Cell/Cellular and Molecular Biology from the University of Pennsylvania in 2003.